Valiant Laboratories Limited
NSE: VALIANTLAB BSE: VALIANTLAB
Prev Close
55.77
Open Price
57.85
Volume
24,046
Today Low / High
53.73 / 57.85
52 WK Low / High
49.51 / 124.4
Range
52 - 58
Prev Close
53.52
Open Price
55.16
Volume
108
Today Low / High
53.58 / 55.16
52 WK Low / High
50 / 123.6
Range
51 - 56
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 54.87 (target range: 52 - 58), reflecting a change of -0.9 (-1.61377%). On the BSE, it is listed at 53.58 (target range: 51 - 56), showing a change of 0.06 (0.11211%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Valiant Laboratories Limited Graph
Valiant Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Valiant Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 54.87, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 53.58 | 54.12 | 48.70 - 59.53 |
| 54.65 | 43.72 - 65.58 | ||
| 55.19 | 38.63 - 71.74 | ||
| Bearish Scenario | 53.58 | 53.04 | 47.74 - 58.35 |
| 52.51 | 42.01 - 63.01 | ||
| 51.97 | 36.38 - 67.56 |
Overview of Valiant Laboratories Limited
ISIN
INE0JWS01017
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
98,300
Market Cap
3,062,681,875
Last Dividend
0
Official Website
IPO Date
2023-10-06
DCF Diff
225.22
DCF
-112
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 138.82 Cr | 116.60 Cr | 22.22 Cr | 0.1600 | 0.00 Cr | 0.00 Cr | 17.83 Cr | -2.20 Cr | -0.51 | 0.76 Cr | -0.0159 |
| 2024-03-31 | 182.06 Cr | 168.25 Cr | 11.58 Cr | 0.0636 | 0.00 Cr | 0.00 Cr | 7.26 Cr | 0.32 Cr | 0.08 | -8.60 Cr | 0.0018 |
| 2023-03-31 | 333.91 Cr | 277.32 Cr | 56.59 Cr | 0.1695 | 0.00 Cr | 0.65 Cr | 50.37 Cr | 29.00 Cr | 6.67 | 39.95 Cr | 0.0868 |
| 2022-03-31 | 291.52 Cr | 239.20 Cr | 52.32 Cr | 0.1795 | 0.00 Cr | 0.48 Cr | 40.01 Cr | 27.50 Cr | 6.33 | 44.27 Cr | 0.0943 |
| 2021-03-31 | 182.37 Cr | 123.98 Cr | 58.39 Cr | 0.3202 | 0.00 Cr | 0.56 Cr | 47.40 Cr | 30.59 Cr | 7.04 | 51.41 Cr | 0.1678 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.92 Cr | 400.86 Cr | 166.55 Cr | 234.3101 Cr | 121.69 Cr | 45.70 Cr | 3.99 Cr | 204.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 59.6157 Cr |
| 2024-03-31 | 11.72 Cr | 342.69 Cr | 105.83 Cr | 236.8612 Cr | 76.71 Cr | 64.99 Cr | 10.02 Cr | 92.70 Cr | 0.00 Cr | 0.00 Cr | -128.67 Cr | 29.0769 Cr |
| 2023-03-31 | 1.26 Cr | 212.97 Cr | 112.48 Cr | 100.4910 Cr | 60.22 Cr | 58.96 Cr | 13.04 Cr | 48.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 50.7260 Cr |
| 2022-03-31 | 20.53 Cr | 181.81 Cr | 110.35 Cr | 71.4600 Cr | 61.13 Cr | 40.59 Cr | 15.80 Cr | 23.67 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 49.4270 Cr |
| 2021-03-31 | 3.94 Cr | 106.31 Cr | 17.73 Cr | 88.5820 Cr | 0.60 Cr | -3.33 Cr | 6.07 Cr | 19.79 Cr | 0.00 Cr | 0.96 Cr | 0.00 Cr | 15.8870 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.3133 Cr | -52.7677 Cr | 44.6528 Cr | -112.5403 Cr | -6.8017 Cr | 4.9165 Cr | -113.8536 Cr | -2.2012 Cr | 29.6858 Cr | 0.0000 Cr | 6.0267 Cr |
| 2024-03-31 | 1.8854 Cr | -143.8768 Cr | 152.4479 Cr | -43.9849 Cr | 10.4566 Cr | 11.7182 Cr | -45.8703 Cr | -0.7695 Cr | 16.6503 Cr | 0.0000 Cr | 3.0270 Cr |
| 2023-03-31 | 56.0511 Cr | -55.1682 Cr | -0.9339 Cr | 18.3702 Cr | -0.0510 Cr | 1.2616 Cr | -37.6809 Cr | 28.9983 Cr | -1.2807 Cr | 0.0000 Cr | 2.7615 Cr |
| 2022-03-31 | 2.2510 Cr | -12.2380 Cr | 6.1810 Cr | -4.6250 Cr | -3.8060 Cr | 0.1310 Cr | -6.8760 Cr | 41.7040 Cr | -42.0720 Cr | 0.0000 Cr | -9.7310 Cr |
| 2021-03-31 | 9.1090 Cr | -16.6690 Cr | 11.4300 Cr | 7.4400 Cr | 3.8690 Cr | 3.9370 Cr | -1.6690 Cr | 47.0230 Cr | 13.2140 Cr | 0.0000 Cr | -2.2040 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 52.46 Cr | 48.97 Cr | 3.50 Cr | 0.0666 | -2.94 Cr | -7.06 Cr | -1.30 | -0.89 Cr | -0.1345 |
| 2025-09-30 | 46.20 Cr | 40.33 Cr | 5.87 Cr | 0.1271 | -0.45 Cr | 0.20 Cr | 0.04 | 0.94 Cr | 0.0043 |
| 2025-06-30 | 46.82 Cr | 39.72 Cr | 7.10 Cr | 0.1516 | 1.87 Cr | 1.82 Cr | 0.39 | 3.05 Cr | 0.0389 |
| 2025-03-31 | 55.47 Cr | 48.23 Cr | 7.25 Cr | 0.1306 | 6.12 Cr | 0.70 Cr | 0.16 | 3.09 Cr | 0.0127 |
| 2024-12-31 | 35.23 Cr | 28.72 Cr | 6.51 Cr | 0.1848 | 0.10 Cr | 2.35 Cr | 0.54 | 2.20 Cr | 0.0666 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3.12 Cr | 59.79 Cr | 62.91 Cr | 55.95 Cr | 27.01 Cr | 193.68 Cr | 221.81 Cr | 424.65 Cr | 107.31 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 75.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -234.31 Cr |
| 2025-03-31 | 4.92 Cr | 71.07 Cr | 75.99 Cr | 72.12 Cr | 3.99 Cr | 192.62 Cr | 204.11 Cr | 400.86 Cr | 166.55 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 118.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -231.61 Cr |
| 2024-09-30 | 2.40 Cr | 116.58 Cr | 118.98 Cr | 0.03 Cr | 5.16 Cr | 191.36 Cr | 162.49 Cr | 360.96 Cr | 129.35 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.70 Cr | 1.31 Cr | -52.77 Cr | 44.65 Cr | 4.92 Cr | 4.92 Cr | 0.00 Cr | -113.85 Cr | -112.54 Cr |
| 2024-12-31 | 2.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -4.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1973
Gender: male
Year Born: 1983
Gender: male
Year Born: 1960
Gender: male
Year Born: 1994
Gender: female
Year Born:
Gender: female
Year Born:
Gender: Not Specified
Year Born:
FAQs about Valiant Laboratories Limited
The CEO is Santosh Shantilal Vora.
The current price is ₹56.39.
The range is ₹53.1-124.4.
The market capitalization is ₹306.27 crores.
The P/E ratio is -70.71.
The company operates in the Healthcare sector.
Overview of Valiant Laboratories Limited (ISIN: INE0JWS01017) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹306.27 crores and an average daily volume of 98,300 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.